Magnetic resonance imaging (MRI) is increasingly being used for prostate cancer diagnosis and for guiding biopsies due to its advantages over traditional prostate-specific antigen (PSA) screening and transrectal ultrasound (TRUS)-guided biopsies in its ability to reliably visualize the whole prostate noninvasively [2,3,4]. The gene discussed is KLK3; the disease is prostate carcinoma.